Can the share price of Sirtex Medical Limited keep climbing higher?

The share price of Sirtex Medical has surged by over 50% this year, however is there more to come?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Following the release of dose sales growth of 27% for the quarter ended 30 June 2014, the market capitalisation of Sirtex Medical Limited (ASX:SRX) has smashed through the $1 billion mark for the first time. Impressively, the Americas saw sales growth of 33%. The share price of Sirtex has increased by a whopping 58% since the start of 2014. The question for investors is whether the share price still represents value, or has the future growth already been factored in following the huge increase over the past 12 months.

Sirtex has now reported 40 consecutive quarters of dose sales growth. Dose sales have been a key measure of the company's performance and have increased from 3,658 in FY09 to 7,299 in FY13.

A key date for Sirtex and investors will be the release of clinical trial results in the first quarter of 2015, which if successful would likely deliver a huge growth in sales for Sirtex and send earnings and the share price rocketing. Currently, the Sirtex treatment is used as a treatment of last resort or as the company describes it "a last line, salvage therapy" with less than 10% of patients eligible for the treatment. However, if the results were successful, the Sirtex product could be used as a "first-line", stage 1 treatment, meaning the product could be used much earlier in the treatment process. This would mean that the potential addressable market for Sirtex would increase significantly.

Macquarie analyst, Craig Collie is confident that the trial results will be positive, backed up by the company tripling their manufacturing capacity later in 2014. However, even if the trial tests were not positive, the company has stated that dose sales growth should continue in line with prior historical growth rates, meaning that Sirtex will continue to grow sales and earnings even if the trial results are negative.

I believe there is certainly plenty of upside to the share price in FY15. A positive trial result would see the shares soar, however a negative result should not see the share price fall signifcantly as the company will continue to grow sales strongly.

Motley Fool contributor Bradley Murphy owns shares in Sirtex Medical.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »